CHCWM – Cancer & Hematology Centers of West Michigan

19951-CL-0101 (Astellas)

Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

APG-1387-US-001 (Ascentage Pharma)

Phase 1 Study of the safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1387 as a Single Agent or In Combinations with systemic Anti-Cancer Agents in Patients with Advanced Solid Tumors or Hematologic Malignancies

AstraZeneca D9268C00001 (TROPION-Breast01)

  A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) PI: Amy VanderWoude Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint

AT1488001 –ALX148 (Alexo)

Phase I, dose escalation study of ALX148 in patients with advanced solid tumors or lymphoma examining safety, pharmacokinetics and tolerability. NOW IN COMBINATION PHASE II WITH PEMBROLIZUMAB, RITUXIMAB AND TRASTUZUMAB


A Phase I Cohort Dose-Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID 200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients with Advanced or Metastatic Solid Tumor Malignancies

BBI-20201001 (Bolt)

Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors

CPG-01-001 – COM701 (Compugen)

A Phase 1a/1b Study of COM701 as Monotherapy and In Combination with an Anti-PD-1Antibody in Subjects with Advanced Solid Tumors